(Q38956348)

7 September 2017

title

Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children (English)

1 reference

pneumococcal conjugate vaccine

7 September 2017

main subject

1 reference

1

1 reference

7 September 2017

2

Nicola Principi

1 reference

7 September 2017

author name string

ESCMID Vaccine Study Group

series ordinal

3

1 reference

7 September 2017

publication date

6 October 2015

1 reference

7 September 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

7 September 2017

volume

10

1 reference

7 September 2017

issue

10

1 reference

7 September 2017

page(s)

1599-1607

1 reference

Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development

7 September 2017

cites work

1 reference

Serotype replacement in disease after pneumococcal vaccination

21 January 2018

1 reference

Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group

21 January 2018

1 reference

Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity

21 January 2018

1 reference

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

21 January 2018

1 reference

Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality

21 January 2018

1 reference

Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance

21 January 2018

1 reference

Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.

21 January 2018

1 reference

National hospitalization trends for pediatric pneumonia and associated complications

21 January 2018

1 reference

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

21 January 2018

1 reference

Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis

21 January 2018

1 reference

Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children

21 January 2018

1 reference

Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a Pediatric Referral Hospital in Uruguay

21 January 2018

1 reference

Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua

21 January 2018

1 reference

Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.

21 January 2018

1 reference

Postexposure Prophylaxis Against Human Immunodeficiency Virus (HIV): New Guidelines From the WHO: A Perspective

21 January 2018

1 reference

Impact of the 13-valent pneumococcal conjugate vaccine on chronic sinusitis associated with Streptococcus pneumoniae in children

21 January 2018

1 reference

Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study

21 January 2018

1 reference

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.

21 January 2018

1 reference

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study.

21 January 2018

1 reference

Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial

21 January 2018

1 reference

Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction

21 January 2018

1 reference

Impact of 13-Valent Pneumococcal Conjugate Vaccination on Streptococcus pneumoniae Carriage in Young Children in Massachusetts.

21 January 2018

1 reference

Changes in pneumococcal nasopharyngeal colonization among children with respiratory tract infections before and after use of the two new extended-valency pneumococcal conjugated vaccines

21 January 2018

1 reference

7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?

21 January 2018

1 reference

Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae

21 January 2018

1 reference

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FMB.15.81

1 reference

7 September 2017

1 reference